October 1, 2021 -- The U.S. Food and Drug Administration (FDA) has designated the Oncuria noninvasive bladder cancer test from Nonagen Bioscience as a breakthrough device.
The company said Oncuria is capable of predicting how a patient will respond to therapy. The multiplex immunoassay measures 10 protein biomarkers in a single voided urine sample.
When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.Yes, Keep Me Current